Back to search results

Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies

IsraelRecruitingPHASE3

Conditions

Heterozygous or Homozygous Familial Hypercholesterolemia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Excel Medical Clinical Trials LLC, Boca Raton, Florida, United States

  • Icahn School of Med at Mt Sinai, New York, New York, United States

  • Cincinnati Childrens Hospital MC, Cincinnati, Ohio, United States

  • Childrens Hosp Pittsburgh UPMC, Pittsburgh, Pennsylvania, United States

  • Primary Childrens Medical Center, Salt Lake City, Utah, United States

  • Novartis Investigative Site, Formosa, Formosa Province, Argentina

  • Novartis Investigative Site, Fortaleza, Ceará, Brazil

  • Novartis Investigative Site, São Paulo, São Paulo, Brazil

  • Novartis Investigative Site, São Paulo, São Paulo, Brazil

  • Novartis Investigative Site, Québec, Quebec, Canada

  • Novartis Investigative Site, Prague, Czechia

  • Novartis Investigative Site, Prague, Czechia

  • Novartis Investigative Site, Besançon, France

  • Novartis Investigative Site, Toulouse, France

  • Novartis Investigative Site, Frankfurt am Main, Hesse, Germany

  • Novartis Investigative Site, Freiburg im Breisgau, Germany

  • Novartis Investigative Site, Athens, Greece

  • Novartis Investigative Site, Athens, Greece

  • Novartis Investigative Site, Pécs, Baranya, Hungary

  • Novartis Investigative Site, Jerusalem, Israel

  • Novartis Investigative Site, Ramat Gan, Israel

  • Novartis Investigative Site, Milan, MI, Italy

  • Novartis Investigative Site, Modena, MO, Italy

  • Novartis Investigative Site, Roma, RM, Italy

  • Novartis Investigative Site, Roma, RM, Italy

  • Novartis Investigative Site, Irbid, Jordan

  • Novartis Investigative Site, Beirut, Lebanon

  • Novartis Investigative Site, Beirut, Lebanon

  • Novartis Investigative Site, Sungai Buloh, Selangor, Malaysia

  • Novartis Investigative Site, Kuala Lumpur, Malaysia

  • Novartis Investigative Site, Amsterdam, North Holland, Netherlands

  • Novartis Investigative Site, Rotterdam, South Holland, Netherlands

  • Novartis Investigative Site, Oslo, Norway

  • Novartis Investigative Site, Gdansk, Poland

  • Novartis Investigative Site, Lodz, Łódź Voivodeship, Poland

  • Novartis Investigative Site, Kemerovo, Russia

  • Novartis Investigative Site, Moscow, Russia

  • Novartis Investigative Site, Poprad, Slovakia

  • Novartis Investigative Site, Ljubljana, Slovenia

  • Novartis Investigative Site, Bloemfontein, Free State, South Africa

  • Novartis Investigative Site, Cape Town, Western Cape, South Africa

  • Novartis Investigative Site, Pamplona, Navarre, Spain

  • Novartis Investigative Site, Oviedo, Principality of Asturias, Spain

  • Novartis Investigative Site, A Coruña, Spain

  • Novartis Investigative Site, Córdoba, Spain

  • Novartis Investigative Site, Geneva, Switzerland

  • Novartis Investigative Site, Taipei, Taiwan

  • Novartis Investigative Site, Istanbul, Fatih, Turkey (Türkiye)

  • Novartis Investigative Site, Adana, Saricam, Turkey (Türkiye)

  • Novartis Investigative Site, Ankara, Yenimahalle, Turkey (Türkiye)

  • Novartis Investigative Site, Izmir, Turkey (Türkiye)

  • Novartis Investigative Site, Middlesex, United Kingdom

Study leads

  • Novartis Pharmaceuticals

    Study Director

    Novartis Pharmaceuticals

View source on ClinicalTrials.gov(opens in a new tab)